



Cogstate Limited
ABN 80 090 975 723

Level 2, 255 Bourke Street
Melbourne Victoria 3000
Australia

P +61 3 9664 1300
F +61 3 9664 1301
W cogstate.com

ASX Announcement

30 April 2020

Unquoted Securities Update – Unquoted Options Forfeited/Expire

Cogstate (ASX:CGS) is reporting that due to cessation of employment or the expiration of the option the following number of Unrestricted Unquoted Options have been forfeited by participants in the Cogstate Employee Option Plan.

- Forfeited **525,000**
- Number and Class of all securities not quoted on ASX
 - Unquoted options
 - Number: **8,065,000**

About Cogstate

Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For nearly 20 years, Cogstate has proudly supporting the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, Cogstate has recently entered into an exclusive licensing agreement with pharmaceutical company, Eisai, under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets. For more information, please visit www.cogstate.com.

For further information contact:

Keith Hawkins
Company Secretary
khawkins@cogstate.com